Ali A. Nasrallah

Ali A. Nasrallah

Auto-generated profile, based on publicly available information

Ali A. Nasrallah

Department of Surgery, Division of Urology, The University of Texas Medical Branch, Galveston, TX

Research Focus & Metrics

Academic Career Length

27Years (2000-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 March 2020 in Cureus
Verified
Journal Article
Open access
PDF file
MCMohamad Chahrour
Mohamad Chahrour
SASahar Assi
Sahar Assi
MBMichael Bejjani
Michael Bejjani
ANAli A Nasrallah
Ali A Nasrallah
HSHamza Salhab
Hamza Salhab
HKHussein Khachfe
Hussein Khachfe
Background: The novel coronavirus disease 2019 (COVID-19) has impacted many countries across all inhabited continents, and is now considered a global pandemic, due to its high rate of infectivity. Research related to this disease is pivotal for assessing pathogenic characteristics and formulating therapeutic strategies. The aim of this paper is to explore the activity and trends of COVID-19 research since its outbreak in December 2019. Methods: We explored the PubMed database and the World Health Organization (WHO) database for publications pertaining to COVID-19 since December 2019 up until March 18, 2020. Only relevant observational and interventional studies were included in our study. Data on COVID-19 incidence were extracted from the WHO situation reports. Research output was assessed with respect to gross domestic product (GDP) and population of each country. Results: Only 564 publications met our inclusion criteria. These articles came from 39 different countries, constituting 24% of all affected countries. China produced the greatest number of publications with 377 publications (67%). With respect to continental research activity, Asian countries had the highest research activity with 434 original publications (77%). In terms of publications per million persons (PPMPs), Singapore had the highest number of publications with 1.069 PPMPs. In terms of publications per billion-dollar GDP, Mauritius ranked first with 0.075. Conclusion: COVID-19 is a major disease that has impacted international public health on a global level. Observational studies and therapeutic trials pertaining to COVID-19 are essential for assessing pathogenic characteristics and developing novel treatment options.

6 January 2022 in World Journal of Urology
Verified
Journal Article
Closed access
PDF file
AHAlbert El Hajj
Albert El Hajj
Vincent MisraiVincent Misrai
Vincent Misrai
ANAli A. Nasrallah
Ali A. Nasrallah
MLMuhieddine L. Labban
Muhieddine L. Labban
JNJad A. Najdi
Jad A. Najdi
EREnrique Rijo
Enrique Rijo

1 January 2022 in Therapeutic Advances in Urology
Verified
Journal Article
Open access
ANAli A. Nasrallah
Ali A. Nasrallah
HDHabib A. Dakik
Habib A. Dakik
NHNassib F. Abou Heidar
Nassib F. Abou Heidar
JNJad A. Najdi
Jad A. Najdi
ONOussama G. Nasrallah
Oussama G. Nasrallah
AHAlbert El Hajj
Albert El Hajj
Introduction: Partial nephrectomy (PN) is associated with a non-negligible risk of postoperative cardiovascular morbidity and mortality. Identification of high-risk patients may enable optimization of perioperative management and consideration of alternative approaches. The authors aim to develop a procedure-specific cardiovascular risk index for PN patients and compare its performance to the widely used revised cardiac risk index (RCRI) and AUB-HAS2 cardiovascular risk index. Methods: The cohort was derived from the American College of Surgeons – National Surgical Quality Improvement Program (ACS-NSQIP) database. The primary outcome was the incidence of major adverse cardiovascular events (MACE), defined as 30-day postoperative incidence of myocardial infarction, stroke, or mortality. A multivariate logistic regression model was constructed; performance and calibration were evaluated using an ROC analysis and the Hosmer–Lemeshow test and compared to the RCRI and the AUB-HAS2 index. Results: In a cohort of 4795 patients, MACE occurred in 52 (1.1%) patients. A univariate analysis yielded 13 eligible variables for entry into the multivariate model. The final PN-A4CH model utilized six variables: Age ⩾75 years, ASA class >2, Anemia, surgical Approach, Creatinine >1.5, and history of Heart disease. Index ROC analysis provided a C-statistic of 0.81, calibration R2 was 0.99, and sensitivity was 85%. In comparison, the RCRI and AUB-HAS2 C-statistics were 0.59 and 0.68, respectively. Conclusion: This study proposes a novel procedure-specific cardiovascular risk index. The PN-A4CH index demonstrated good predictive ability and excellent calibration using a large national database and may enable further individualization of patient care and optimization of patient selection.

10 January 2000 in American Journal of Hematology
Verified
Journal Article
Open access
PDF file
Ali TaherAli Taher
Ali Taher
ZAZ. Ammash
Z. Ammash
BDB. Dabajah
B. Dabajah
ANA. Nasrallah
A. Nasrallah
FMFadi H. Mourad
Fadi H. Mourad
We report here a case of ticlopidine‐induced aplastic anemia that responded to G‐CSF and review the literature. An 83‐year‐old woman was started on ticlopidine for coronary artery disease after an episode of upper gastrointestinal bleeding secondary to aspirin. She developed aplastic anemia seven weeks after initiation of ticlopidine. She was hospitalised and received empiric antibiotic therapy and granulocyte colony stimulating factor (G‐CSF). Her bone marrow started to recover quickly, and white blood cell and platelet counts returned to normal within three weeks. A review of medical literature revealed 20 similar cases of ticlopidine‐induced aplastic anemia resulting in death in seven cases. G‐CSF has been used previously with variable success. Ticlopidine is associated with serious, sometimes fatal hematological side effects. This risk should be seriously taken into consideration when prescribing ticlopidine. G‐CSF may be helpful in the treatment of ticlopidine‐induced aplastic anemia. Am. J. Hematol. 63:90–93, 2000.

4 March 2022 in European Journal of Obstetrics & Gynecology and Reproductive Biology
Verified
Journal Article
Closed access
KDKarim Seif El Dahan
Karim Seif El Dahan
JBJoseph Bejjani
Joseph Bejjani
ANAli A. Nasrallah
Ali A. Nasrallah
LYLara Youssef
Lara Youssef
AMAndrea Mladenovic
Andrea Mladenovic
AJAbdo Jurjus
Abdo Jurjus

1 March 2025 in JU Open Plus
Verified
Journal Article
Open access
ANAli A. Nasrallah
Ali A. Nasrallah
SDSanjay Das
Sanjay Das
CEClaire Evans
Claire Evans
LGLin Gu
Lin Gu
JPJoshua A. Parrish
Joshua A. Parrish
SWStephen B. Williams
Stephen B. Williams
Purpose: The purpose of this study was to compare the impact of blue light cystoscopy (BLC) vs white light cystoscopy (WLC) on the oncologic outcomes of nonmuscle invasive bladder cancer (NMIBC). Materials and Methods: We identified patients diagnosed with NMIBC between 1997 and 2021 in the Veterans Affairs Healthcare System. A 1:1 propensity score matching algorithm was used, accounting for baseline demographic and clinical variables. The primary objective was to determine recurrence and progression-free survival, using multivariable Cox proportional hazards regression models. Results: Among 626 matched patients (313 BLC and 313 WLC), median age at diagnosis was 71 years, 616 (98%) were male, 381 (61%) were high-risk NMIBC, and 159 (25%) had bladder cancer recurrence. Median follow-up was 3.7 years. Recurrence risk at 3 years was significantly reduced after BLC vs WLC (hazard ratio = 0.62; 95% confidence interval, 0.45-0.86; P < .01). Progression risk at 3 years was reduced; however, this was not statistically significant (hazard ratio = 0.71; 95% confidence interval, 0.37-1.38; P = .32). Compared with WLC patients, BLC patients were significantly more likely to receive intravesical Bacillus Calmette-Guerin (61% vs 43%; P < .01) or intravesical chemotherapy (48% vs 27%, P < .01). No difference in definitive treatment rates (radical cystectomy, radiation therapy, and/or systemic chemotherapy) was observed (8% vs 6%; P = .27) between BLC and WLC patients. Conclusions: In a high-risk NMIBC predominant cohort, the use of BLC was associated with reduced risk of bladder cancer recurrence. BLC use was also associated with increased use of intravesical therapies but not definitive treatment. These findings provide evidence for the oncologic benefits of using BLC.